drugset / Trial / NCT00397553

Insulin Glulisine, Diabetes Mellitus Type 1

NCT00397553

Phase 3 Completed 104 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy

Timeline

Start
2005-01
Primary completion
2007-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic Subcutaneous